Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 9Arthralgia 2Osteoporosis 1Neurotoxicity Syndromes 1Neoplasm Metastasis 1Hormone-receptor-positive Breast Cancer 1Hormone Receptor Positive Advanced Breast Cancer 1Fractures, Bone 1Fatigue 1Endometrial Neoplasms 1Advanced Breast Cancer 1

Interventions

Blood Specimen Collection 7Drug Therapy 6Surveys and Questionnaires 5Radiotherapy 5Radiosurgery 5Docetaxel 5Therapeutics 4Specimen Handling 4Immunotherapy 4Hepatectomy 4exemestane 3enzalutamide 3apalutamide 3Trastuzumab 3Hematologic Tests 3Data Collection 3Biopsy 3Biological Assay 3Anastrozole 3Abiraterone Acetate 3trastuzumab deruxtecan 2palbociclib 2darolutamide 2abiraterone 2abemaciclib 2Wearable Electronic Devices 2Triptorelin Pamoate 2Tamoxifen 2Surgical Procedures, Operative 2Radiotherapy, Intensity-Modulated 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Neoplasm Metastasis × Aromatase Inhibitors × Clear all
NCT06086340 2025-11-18

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Pfizer

Completed
779 enrolled 9 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡